Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates

Pathological forms of Tau protein are directly associated with neurodegeneration and correlate with Alzheimer’s Disease (AD) symptoms, progression, and severity. Previously, using various mouse models of Tauopathies and AD, we have demonstrated the immunogenicity and efficacy of the MultiTEP-based a...

Full description

Saved in:
Bibliographic Details
Published in:npj vaccines 2022-10, Vol.7 (1), p.117-10, Article 117
Main Authors: Hovakimyan, Armine, Zagorski, Karen, Chailyan, Gor, Antonyan, Tatevik, Melikyan, Levon, Petrushina, Irina, Batt, Dash G., King, Olga, Ghazaryan, Manush, Donthi, Aashrit, Foose, Caitlynn, Petrovsky, Nikolai, Cribbs, David H., Agadjanyan, Michael G., Ghochikyan, Anahit
Format: Article
Language:English
Subjects:
631/250/590/2294
631/61/24/590/2294
Alzheimer's disease
Biomedical and Life Sciences
Biomedicine
Clinical trials
Immune system
Immunity (Disease)
Immunogenicity
Infectious Diseases
Medical Microbiology
Primates
Public Health
Vaccine
Vaccines
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pathological forms of Tau protein are directly associated with neurodegeneration and correlate with Alzheimer’s Disease (AD) symptoms, progression, and severity. Previously, using various mouse models of Tauopathies and AD, we have demonstrated the immunogenicity and efficacy of the MultiTEP-based adjuvanted vaccine targeting the phosphatase activating domain (PAD) of Tau, AV-1980R/A. Here, we analyzed its immunogenicity in non-human primates (NHP), the closest phylogenic relatives to humans with a similar immune system, to initiate the transition of this vaccine into clinical trials. We have demonstrated that AV-1980R/A is highly immunogenic in these NHPs, activating a broad but unique to each monkey repertoire of MultiTEP-specific T helper (Th) cells that, in turn, activate B cells specific to PAD. The resulting anti-PAD IgG antibodies recognize pathological Tau tangles and Tau-positive neuritis in AD case brain sections with no staining in control non-AD cases. These published data and efficacy results support the AV-1980R/A vaccine progression to first-in-human clinical trials.
ISSN:2059-0105
2059-0105
DOI:10.1038/s41541-022-00544-3